Clinical trial
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
NCT00017537 · University of Alabama at Birmingham, Other · Withdrawn
Key facts
| NCT number | NCT00017537 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer |
| Official title | Phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | MVF-HER-2(628-647)-CRL 1005 vaccine |
| Enrollment | 0 |
| Start date | Mar 1, 2000 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jan 8, 2004 |
| Last update posted | Aug 5, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: